Literature DB >> 27256701

Response to 'PET after response to R-CHOP in primary mediastinal large B-cell lymphoma'.

T P Vassilakopoulos1, S Papageorgiou2, G A Pangalis3, S Chatziioannou4, M K Angelopoulou1, P Panayiotidis5, K Konstantopoulos1, P Rondogianni6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27256701     DOI： 10.1038/leu.2016.109

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

1.  Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study.

Authors:  M Rieger; A Österborg; R Pettengell; D White; D Gill; J Walewski; E Kuhnt; M Loeffler; M Pfreundschuh; A D Ho
Journal:  Ann Oncol       Date:  2010-08-19       Impact factor: 32.976

2.  Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care.

Authors:  Theodoros P Vassilakopoulos; Gerassimos A Pangalis; Andreas Katsigiannis; Sotirios G Papageorgiou; Nikos Constantinou; Evangelos Terpos; Alexandra Zorbala; Effimia Vrakidou; Panagiotis Repoussis; Christos Poziopoulos; Zacharoula Galani; Maria N Dimopoulou; Stella I Kokoris; Sotirios Sachanas; Christina Kalpadakis; Evagelia M Dimitriadou; Marina P Siakantaris; Marie-Christine Kyrtsonis; John Dervenoulas; Meletios A Dimopoulos; John Meletis; Paraskevi Roussou; Panayiotis Panayiotidis; Photis Beris; Maria K Angelopoulou
Journal:  Oncologist       Date:  2012-01-26

3.  Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients.

Authors:  Hee Kyung Ahn; Seok Jin Kim; Jina Yun; Jun Ho Yi; Jung-Hoon Kim; Young-Woong Won; Kihyun Kim; Young Hyeh Ko; Won Seog Kim
Journal:  Int J Hematol       Date:  2010-03-03       Impact factor: 2.490

4.  Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients.

Authors:  Wai Meng Tai; Daniel Quah; Swee Peng Yap; Sze Huey Tan; Tiffany Tang; Kuang Wei Tay; Yu Xuan Koo; Miriam Tao; Richard Quek; Soon Thye Lim
Journal:  Leuk Lymphoma       Date:  2011-01-24

5.  PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy.

Authors:  T P Vassilakopoulos; G A Pangalis; S Chatziioannou; S Papageorgiou; M K Angelopoulou; Z Galani; G Kourti; V Prassopoulos; T Leonidopoulou; E Terpos; M N Dimopoulou; S Sachanas; C Kalpadakis; P Konstantinidou; D Boutsis; E Stefanoudaki; L Kyriazopoulou; M P Siakantaris; M-C Kyrtsonis; E Variami; I Kotsianidis; A Symeonidis; E Michali; E Katodritou; G Kokkini; C Tsatalas; H Papadaki; M-A Dimopoulos; V Sotiropoulos; V Pappa; T Karmiris; J Meletis; J Apostolidis; I Datseris; P Panayiotidis; K Konstantopoulos; P Roussou; P Rondogianni
Journal:  Leukemia       Date:  2015-05-14       Impact factor: 11.528

6.  PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP.

Authors:  K Lontos
Journal:  Leukemia       Date:  2016-05-17       Impact factor: 11.528

7.  [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.

Authors:  Maurizio Martelli; Luca Ceriani; Emanuele Zucca; Pier Luigi Zinzani; Andrés J M Ferreri; Umberto Vitolo; Caterina Stelitano; Ercole Brusamolino; Maria Giuseppina Cabras; Luigi Rigacci; Monica Balzarotti; Flavia Salvi; Silvia Montoto; Armando Lopez-Guillermo; Erica Finolezzi; Stefano A Pileri; Andrew Davies; Franco Cavalli; Luca Giovanella; Peter W M Johnson
Journal:  J Clin Oncol       Date:  2014-05-05       Impact factor: 44.544

8.  Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.

Authors:  Chelsea C Pinnix; Bouthaina Dabaja; Mohamed Amin Ahmed; Hubert H Chuang; Colleen Costelloe; Christine F Wogan; Valerie Reed; Jorge E Romaguera; Sattva Neelapu; Yasuhiro Oki; M Alma Rodriguez; Luis Fayad; Frederick B Hagemeister; Loretta Nastoupil; Francesco Turturro; Nathan Fowler; Michelle A Fanale; Yago Nieto; Issa F Khouri; Sairah Ahmed; L Jeffrey Medeiros; Richard Eric Davis; Jason Westin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-05-01       Impact factor: 7.038

9.  Prognostic Role of Pre-Radiation Therapy (18)F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation.

Authors:  Andrea Riccardo Filippi; Cristina Piva; Mario Levis; Annalisa Chiappella; Daniele Caracciolo; Marilena Bellò; Gianni Bisi; Umberto Vitolo; Umberto Ricardi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-03-02       Impact factor: 7.038

10.  Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease.

Authors:  Jacob D Soumerai; Matthew D Hellmann; Yang Feng; Aliyah R Sohani; Christiana E Toomey; Jeffrey A Barnes; Ronald W Takvorian; Donna Neuberg; Ephraim P Hochberg; Jeremy S Abramson
Journal:  Leuk Lymphoma       Date:  2013-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.